News
October 17, 2016
Toronto, October 17, 2016 – Greater regulatory convergence is needed to ensure a consistent supply of safe, effective and high-quality generic medicines in Canada, according to a new study prepared by Deloitte LLP and commissioned by the Canada Generic Pharmaceutical Association (CGPA).
September 12, 2016
Toronto, September 12, 2016 – Brand-name drug companies’ research and development spending as a percentage of sales in Canada is less than half of the 10% the industry committed to when their periods of market exclusivity were increased in 1987, according to the most recent annual report from the federal government’s Patented Medicine Prices Review Board (PMPRB).
February 9, 2016
Toronto, February 9, 2016 – A new report released today by the federal government’s Patented Medicine Prices Review Board (PMPRB) highlights the success achieved by Canada’s provincial and territorial governments through their agreement with the Canadian Generic Pharmaceutical Association (CGPA).
January 19, 2016
Montreal, January 19, 2016 – – According to a study released today, the proposed removal of the limit on professional allowance payments to pharmacies would be a form of "tax" imposed on generic drug manufacturers that could potentially threaten jobs and investments in Quebec.
January 11, 2016
Toronto, January 11, 2016 – Brand-name drug companies’ research and development spending as a percentage of sales in Canada has dropped to new historic lows according to the most recent annual report from the federal government’s Patented Medicine Price Review Board (PMPRB).